Teva Wants Strict FDA Review For Biogen's Rival MS Drug
Teva Pharmaceutical Industries Ltd. is imploring the U.S. Food and Drug Administration not to approve any new multiple sclerosis drugs without first consulting an advisory committee of independent experts, a move...To view the full article, register now.
Already a subscriber? Click here to view full article